• Profile
Close

Efficacy of ADAM zolmitriptan for the acute treatment of difficult-to-treat migraine headaches

Headache: The Journal of Head and Face Pain Feb 04, 2019

Tepper SJ, et al. - In these post hoc analyses of subgroups of patients with each of these characteristics in the ZOTRIP trial, zolmitriptan applied with Adhesive Dermally Applied Microarray (ADAM: an investigational system for intracutaneous drug administration) was investigated for its efficacy in treating types of migraine (those with severe headache pain, the presence of nausea, treatment ≥2 hours after migraine onset, or migraine present upon awakening) that are historically considered to be less responsive to oral medications. Researchers identified a poorer response to acute migraine treatment in correlation with factors like severe pain, delayed treatment, awakening with a headache, and the presence of nausea. Compared with participants receiving placebo, those who received ADAM zolmitriptan 3.8 mg exhibited nearly uniformly better headache responses (2-hour headache freedom and 2-hour MBS freedom) .
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay